Publications by authors named "L Bastian Manso"
Objective: This systematic review aims to evaluate the proactive or real-time assessment of patient reported outcomes in studies involving patients with ovarian cancer undergoing systemic therapy.
Methods: PubMed, Embase, and Cochrane databases were searched (from database inception until February 2022), and prospective ovarian cancer studies (experimental or observational) that incorporated patient reported outcomes, including quality of life, were included. The primary objective was to assess the ratio of studies incorporating real-time use of patient reported outcomes among those studies performing patient reported outcomes.
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
J Clin Oncol
December 2024
Purpose: To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.
Methods: The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months.
Article Synopsis
- This study looked at how a medicine called nintedanib might help with breast cancer by making the environment around the tumor less stiff.
- Researchers tested this by comparing two groups of patients: one got regular treatment while the other received nintedanib with their treatment.
- They found that although overall survival rates were similar, patients with high stiffness scores (MeCo) had a higher risk of cancer returning, but taking nintedanib lowered that risk.
Article Synopsis
- The DESTINY-PanTumor02 study investigated trastuzumab deruxtecan (T-DXd) for treating HER2-expressing solid tumors in patients who had prior treatment, focusing on IHC 3+ and 2+ tumors across seven cancer types.
- Results showed a higher objective response rate (ORR) in patients with IHC 3+ tumors (51.4%) compared to those with IHC 2+ tumors (26.5%), with median durations of response of 14.2 months and 9.8 months, respectively.
- The study concluded that T-DXd provides significant clinical benefit, especially for patients with HER2 IHC 3+ tumors, reinforcing its therapeutic potential
Article Synopsis
- - Cervical cancer (CC) is the fourth most prevalent cancer globally among women and is largely caused by high-risk human papillomavirus (HPV) infections, with significant mortality rates especially in developing countries lacking HPV vaccination and screening programs.
- - Treatment for early-stage CC typically involves surgery or radiotherapy, while locally advanced cases usually require concurrent chemo-radiotherapy, with immunotherapy expected to enhance treatment options soon.
- - This guideline aims to present crucial insights on the diagnosis, treatment, and follow-up of CC, offering evidence-based recommendations to improve clinical practices.